-
JBCRG-C03
Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)
- Status
-
Study Closed
- Objectives
-
To investigate the relevance between histopathological antitumor effect and prognosis in HER2-positive primary breast cancer patients who received trastuzumab and cytotoxic anticancer drug combination therapy before surgery
- Subjects
-
- Endpoints
-
"1st: OS, 2nd: 1) RFS, 2）OS, 3）histologic antitumor effect predictors
4）Occurrence of local / regional recurrence and duration of onset
5）Presence of brain metastasis and duration of expression"
- Trial Period
-
Aug 2011-Jan 2012
- Lead Principal Investigator
-
Dr. Masakazu Toi (Kyoto Univ Hosp)
- Target Sample Size
-
1000
- Regimen
-
Trastuzumab ＋Cytotoxic anticancer drug
- Source of Funding
-
Clinical Trial of Ministry of Health, Labour and Welfare, also supported by JBCRG
- Conference Presentation
-
- Articles and Publications
-
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
- UMIN-ID
-
- jRCT
-
- Memo
-
- COI Disclosure
-
